IMCRC activate launches with innovative first approved project: rapid COVID-19 test


Druglizer Antigen Test, Source: Alcolizer

New funding initiative designed to accelerate and support Australian manufacturers through COVID recovery.

Today we launched our new funding initiative, IMCRC activate, with an Australian first — the development of a rapid COVID-19 test that uses optical technology.

Designed to provide a much-needed stimulus to Australian manufacturing businesses in the wake of COVID-19, IMCRC activate stimulates and fast-tracks R&D investment, offering access to valuable expertise and matched cash funding between $50,000 and $150,000.

The first approved project of the initiative is led by Alcolizer, a Perth-based company developing a rapid saliva test for SARS-CoV-2 virus antigens using its existing drug testing technology.

Alcolizer’s partnership with IMCRC and research collaboration with the University of Technology Sydney (UTS) will see the project accelerate quickly in the face of the global health pandemic, evolving from a proof of concept to secure Good Manufacturing Practice (GMP) readiness in just four months.

As Australia emerges from the worst of the COVID-19 crisis, providing valuable and strategic support for shorter-term research projects in advanced manufacturing and digital technologies is a priority for IMCRC.

David Chuter, CEO and Managing Director of IMCRC, commented: “As the fourth largest industry in Australia, manufacturing is critical to rebuilding the health of our economy.

COVID-19 highlighted some serious capability gaps in the industry, and now we must focus on using our Australian resources and R&D strengths for future growth. The IMCRC activate funding initiative has been designed to do just that — provide funding and pathways for manufacturers to recover and thrive.